Insider Trading Alert - MBLX, LYB And IPAS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 23, 2015, 55 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $468.00 to $511,200,530.33.

Highlighted Stocks Traded by Insiders:

Metabolix (MBLX) - FREE Research Report

Schuler Jack W, who is 10% Owner at Metabolix, bought 1.7 million shares at $3.32 on June 23, 2015. Following this transaction, the 10% Owner owned 2.2 million shares meaning that the stake was boosted by 319.66% with the 1.7 million-share transaction.

Schuler Family Foundation, who is 10% Owner at Metabolix, bought 1.7 million shares at $3.32 on June 23, 2015. Following this transaction, the 10% Owner owned 9.8 million shares meaning that the stake was boosted by 20.5% with the 1.7 million-share transaction.

The shares most recently traded at $4.38, up $1.06, or 24.2% since the insider transaction. Historical insider transactions for Metabolix go as follows:

  • 4-Week # shares bought: 4.5 million
  • 12-Week # shares bought: 4.5 million
  • 24-Week # shares bought: 4.5 million

The average volume for Metabolix has been 29,100 shares per day over the past 30 days. Metabolix has a market cap of $101.7 million and is part of the basic materials sector and chemicals industry. Shares are up 78.21% year-to-date as of the close of trading on Thursday.

Metabolix, Inc., an advanced biomaterials company, focuses on delivering sustainable solutions to the plastics industry. The company develops and commercializes technologies for the production of polymers and chemicals in microbes and plants. Currently, there are no analysts who rate Metabolix a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MBLX - FREE

TheStreet Quant Ratings rates Metabolix as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Metabolix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LyondellBasell Industries (LYB) - FREE Research Report

Smolik Samuel L., who is SVP, Am Mfg & Refining Ops at LyondellBasell Industries, sold 20,000 shares at $105.00 on June 23, 2015. Following this transaction, the SVP, Am Mfg & Refining Ops owned 7,499 shares meaning that the stake was reduced by 72.73% with the 20,000-share transaction.

The shares most recently traded at $104.83, down $0.17, or 0.16% since the insider transaction. Historical insider transactions for LyondellBasell Industries go as follows:

  • 4-Week # shares bought: 17
  • 4-Week # shares sold: 4.1 million
  • 12-Week # shares bought: 17
  • 12-Week # shares sold: 4.1 million
  • 24-Week # shares bought: 17
  • 24-Week # shares sold: 4.1 million

The average volume for LyondellBasell Industries has been 3.4 million shares per day over the past 30 days. LyondellBasell Industries has a market cap of $49.7 billion and is part of the basic materials sector and chemicals industry. Shares are up 31.57% year-to-date as of the close of trading on Tuesday.

LyondellBasell Industries N.V. operates as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers. The stock currently has a dividend yield of 2.97%. The company has a P/E ratio of 12.1. Currently, there are 7 analysts who rate LyondellBasell Industries a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LYB - FREE

TheStreet Quant Ratings rates LyondellBasell Industries as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, increase in net income, notable return on equity and attractive valuation levels. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full LyondellBasell Industries Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

iPass (IPAS) - FREE Research Report

Kaplan Evan, who is Shareholder at iPass, sold 39,046 shares at $1.10 on June 23, 2015. Following this transaction, the Shareholder owned 653,675 shares meaning that the stake was reduced by 5.64% with the 39,046-share transaction.

The shares most recently traded at $1.08, down $0.02, or 1.85% since the insider transaction. Historical insider transactions for iPass go as follows:

  • 4-Week # shares bought: 70,000
  • 4-Week # shares sold: 90,752
  • 12-Week # shares bought: 70,000
  • 12-Week # shares sold: 90,752
  • 24-Week # shares bought: 260,000
  • 24-Week # shares sold: 98,252

The average volume for iPass has been 131,300 shares per day over the past 30 days. iPass has a market cap of $70.1 million and is part of the technology sector and telecommunications industry. Shares are down 21.17% year-to-date as of the close of trading on Tuesday.

iPass Inc. provides cloud-based mobility management and network connectivity services to enterprises and telecommunication carriers in the United States and internationally. Currently, there are no analysts who rate iPass a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPAS - FREE

TheStreet Quant Ratings rates iPass as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full iPass Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing